Robust induction of neutralizing antibodies against the SARS-CoV-2 Delta variant after homologous Spikevax or heterologous Vaxzevria-Spikevax vaccination

Eur J Immunol. 2022 Feb;52(2):356-359. doi: 10.1002/eji.202149645. Epub 2022 Jan 7.

Abstract

Sera of vaccines were assessed by surrogate virus neutralization tests for their capacity to neutralize the SARS-CoV-2 Delta variant. Homologous prime-boost immunization with Moderna's Spikevax as well as heterologous immunization with AstraZeneca's Vaxzevria followed by Moderna's Spikevax were identified as highly potent vaccination regimens for the induction of Delta-neutralizing antibodies.

Keywords: SARS-CoV-2; antibodies; vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing / blood*
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / blood*
  • Antibodies, Viral / immunology
  • COVID-19 / blood*
  • COVID-19 / immunology
  • COVID-19 / prevention & control
  • COVID-19 Vaccines / administration & dosage*
  • Female
  • Humans
  • Male
  • SARS-CoV-2 / immunology
  • SARS-CoV-2 / metabolism*
  • Vaccination*

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 Vaccines

Supplementary concepts

  • SARS-CoV-2 variants